BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ImmunityBio readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies ImmunityBio's drugs run\, from Cl
 inicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06829823-2051@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 2 readout est. (NCT06
 829823)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 2\, Bladder Canc
 er.\nStudy: Clinical Trial of Ablation Therapy in Participants With Interm
 ediate-Risk Non-Muscle Invasive Papillary Bladder Cancer\nEstimated primar
 y completion: November 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/nogapendekin-alfa-inbakicept-anktiva#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06829823
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07123727-2051@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 2 readout est. (NCT07
 123727)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 2.\nStudy: A Stu
 dy to Examine Anktiva for the Treatment of COVID-19.\nEstimated primary co
 mpletion: March 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /nogapendekin-alfa-inbakicept-anktiva#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07123727
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06710288-2051@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 2 readout est. (NCT06
 710288)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 2.\nStudy: A Pha
 se 2\, Open-label\, Single-arm Study Of Autologous M-CENK Adoptive Cell Th
 erapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Pa
 rticipants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer\nEs
 timated primary completion: May 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06710288
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07125872-2204@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20270525
DTEND;VALUE=DATE:20270526
SUMMARY:Hank: Phase 2 readout est. (NCT07125872)
DESCRIPTION:Hank\, phase 2.\nStudy: Study of Relapsed/ Refractory B-cell No
 n- Hodgkin Lymphoma\nEstimated primary completion: 25 May 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/hank#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07125872
URL:https://assetmemo.bio/drug/hank#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07477366-2051@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 2 readout est. (NCT07
 477366)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 2.\nStudy: Study
  of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-H
 odgkin Lymphoma\nEstimated primary completion: December 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-ankt
 iva#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07477366
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07783789-2051@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20280512
DTEND;VALUE=DATE:20280513
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 2 readout est. (NCT07
 783789)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 2.\nStudy: NAI P
 lus Standard of Care Compared To SOC Alone Plus Standard of Care in Critic
 ally Ill Adults With Sepsis\nEstimated primary completion: 12 May 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/nogapendekin-alfa-inbak
 icept-anktiva#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07783789
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06745908-2051@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 3 readout est. (NCT06
 745908)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 3\, Non-Small Ce
 ll Lung Cancer.\nStudy: Clinical Trial of N-803 Plus Tislelizumab or Prior
  Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monothe
 rapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cance
 r Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy\nEst
 imated primary completion: September 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06745908
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-2051@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 2 readout est. (NCT03
 228667)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 2\, Non-Small Ce
 ll Lung Cancer.\nStudy: QUILT-3.055: A Study of Combination Immunotherapie
 s in Patients Who Have Previously Received Treatment With Immune Checkpoin
 t Inhibitors\nEstimated primary completion: 31 August 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiv
 a#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03
 228667
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06061809-2051@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 2 readout est. (NCT06
 061809)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 2.\nStudy: N-803
  and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive G
 lioblastoma\nEstimated primary completion: 31 December 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-ankti
 va#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6061809
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07628062-2051@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 2 readout est. (NCT07
 628062)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 2.\nStudy: Phase
  2 Study of NAI\, HPV Vaccine\, and Nab-Paclitaxel in HPV-Positive Orophar
 yngeal Cancer Followed by De-Intensified Radiation Compared With Standard 
 Chemoradiation\nEstimated primary completion: 31 December 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-an
 ktiva#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07628062
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
